Literature DB >> 18695118

Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.

Lingkun Kong, Helen A Mintz-Hittner, Rebecca L Penland, Francis L Kretzer, Patricia Chévez-Barrios.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18695118     DOI： 10.1001/archophthalmol.2008.1

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  24 in total

1.  Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.

Authors:  T R Padhi; T Das; S Rath; L Pradhan; S Sutar; K G Panda; R Modi; S Jalali
Journal:  Eye (Lond)       Date:  2015-11-20       Impact factor: 3.775

2.  [Acute retinopathy of prematurity].

Authors:  B Lorenz
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

3.  Pulmonary surfactant protein a is expressed in mouse retina by Müller cells and impacts neovascularization in oxygen-induced retinopathy.

Authors:  Faizah Bhatti; Genevieve Ball; Ronald Hobbs; Annette Linens; Saad Munzar; Rizwan Akram; Alistair J Barber; Michael Anderson; Michael Elliott; Madeline Edwards
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-18       Impact factor: 4.799

4.  Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography.

Authors:  Aslı Vural; İrfan Perente; İsmail Umut Onur; Erdem Eriş; Zeynep Seymen; Gülsüm Oya Hergünsel; Özgül Salihoğlu; Fadime Ulviye Yiğit
Journal:  Int Ophthalmol       Date:  2018-11-26       Impact factor: 2.031

5.  Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.

Authors:  Hossein Nazari; Mehdi Modarres; Mohammad Mehdi Parvaresh; Khalil Ghasemi Falavarjani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-27       Impact factor: 3.117

6.  Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.

Authors:  Aslı Vural; Dilbade Yıldız Ekinci; Ismail Umut Onur; Gülsüm Oya Hergünsel; Fadime Ulviye Yiğit
Journal:  Int Ophthalmol       Date:  2019-01-02       Impact factor: 2.031

7.  Reply: Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.

Authors:  Helen A Mintz-Hittner
Journal:  Retina       Date:  2009-04       Impact factor: 4.256

Review 8.  The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment.

Authors:  Lois E Smith; Anna-Lena Hard; Ann Hellström
Journal:  Clin Perinatol       Date:  2013-06       Impact factor: 3.430

9.  Experimental histopathological study on retinal and renal cellular response to intravitreous antiangiogenic drugs.

Authors:  João Borges Fortes Filho; Mauricio Maia; Marcia Beatriz Tartarella; Fabíola Schons Meyer; Bárbara Gastal Borges Fortes; Lúcia Maria Kliemann
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

Review 10.  Emerging treatments for retinopathy of prematurity.

Authors:  Iason S Mantagos; Deborah K Vanderveen; Lois E H Smith
Journal:  Semin Ophthalmol       Date:  2009 Mar-Apr       Impact factor: 1.975
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.